In the previous and present studies, we used anti-human CD90 antibody to isolate CD90+CSCs and CD90+NTSCs from patient tumor tissues because CD90 is a surface marker for hepatic stem cells (oval cells) [30]. This evidence concerns the gene THY1 and neoplasm.